You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 145 No. 4, April 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Total Iron-Binding Capacity in Iron Poisoning

Is It Useful?

Milton Tenenbein, MD, FRCPC, FAAP; Randall W. Yatscoff, PhD, FCACB

Am J Dis Child. 1991;145(4):437-439.


Abstract

• Traditionally, a serum iron concentration in excess of the total iron-binding capacity (TIBC) is considered as an indication for deferoxamine therapy in acute iron poisoning. We observed a reversible elevation of the TIBC in patients with iron poisoning that coincided with their acute hyperferremia and have hypothesized that this is a laboratory aberration. We tested this hypothesis in vitro and found that the addition of iron to test serum samples produced a related increase in the TIBC, and alteration of the assay by providing additional adsorbent prevented this occurrence. We also evaluated the reproducibility of the TIBC as performed by 500 laboratories on 10 different reference samples. The mean coefficient of variation was 16%, which was unsatisfactory. We concluded that the TIBC should not be used in the decision for the initiation of deferoxamine therapy in acute iron poisoning. Furthermore, high TIBC values that are occasionally seen in patients with iron poisoning should not be considered as providing a protective effect.

(AJDC. 1991;145:437-439)



Author Affiliations

From the Departments of Pediatrics (Dr Tenenbein), Medicine (Drs Tenenbein and Yatscoff), and Clinical Chemistry (Dr Yatscoff), University of Manitoba, Winnipeg, and The Manitoba Poison Control Centre, Winnipeg (Dr Tenenbein).


Footnotes

Accepted for publication November 27, 1990.

Presented at the annual scientific meeting of the American Academy of Clinical Toxicology, Atlanta, Ga, October 12, 1989.

Reprint requests to Children's Hospital, 840 Sherbook St, Winnipeg, Manitoba, Canada R3A 1S1 (Dr Tenenbein).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.